Core Viewpoint - Charoen Pokphand Enterprises International (03839) expects to achieve an unaudited net profit attributable to shareholders of approximately $23.5 million for the nine months ending September 30, 2025, a significant increase compared to $4.3 million for the same period in 2024, driven by substantial revenue growth from successful implementation of key strategies targeting large clients [1] Financial Performance - The expected net profit for the nine months ending September 30, 2025, is approximately $23.5 million, up from $4.3 million for the nine months ending September 30, 2024 [1] - The anticipated unaudited quarterly net profit for the three months ending September 30, 2025, is expected to decrease to about $6.5 million, down from $9.3 million for the three months ending June 30, 2025 [1] Market Conditions - The growth in profit is primarily attributed to a significant increase in revenue, reflecting the successful implementation of strategies aimed at developing large client sales [1] - However, there is a noted decrease in demand for the company's veterinary pharmaceutical products due to a slowdown in China's livestock industry, which began to impact demand from the third quarter of 2025 [1]
正大企业国际发盈喜，预期前三季度股东应占综合溢利约2350万美元 同比增加